Eloxx Pharmaceuticals Inc (NASDAQ:ELOX)
| 5.11 Delayed Data As of Sep 26 |  +0.27 / +5.58%Today’s Change | 1.70 Today|||52-Week Range 10.90 | +180.77% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $14.0M |
Company Description
Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid-modulating drug candidates. The firm focuses on the the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. Its lead product candidate is ELX-02, a small molecule drug designed to restore production of full-length functional proteins. It operates through the United States and Israel geographical segments. The company was founded by Silvia Noiman on December 19, 2017 and is headquartered in Watertown, MA.
Contact Information
Eloxx Pharmaceuticals, Inc. 480 Arsenal Way Watertown Massachusetts 02451 |
Employees
Shareholders
| Other institutional | 7.14% |
| Mutual fund holders | 1.49% |
| Individual stakeholders | 0.35% |
Top Executives
| Sumit Aggarwal | President, Chief Executive Officer & Director |
| Daniel E. Geffken | Chief Financial & Accounting Officer |
| Vijay Modur | Head-Research & Development |
| Ali Hariri | Chief Medical Officer |
| Barbara Ryan | Investor Relations Contact |
